EUVIMEDEUVIMED entdecken
Crossref

Structure–Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2 H ,4 H )-dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer

Xiaobao Zhao, Changxin Zhong, Rongfeng Zhu, Rong Gong, Bingyan Liu, Linhao He, Sheng Tian, Jing Jin, Ting Jiang, Jing-Lei Chen, Xiaoya Wan, Wenjing Liu und 4 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01484 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Xiaobao Zhao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Su…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Elongation Factor 2 Kinase, Triazines, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Fundamental Research Funds for Central Universities of the Central South University, Natural Science Foundation of Hunan Province, Hunan Provincial Innovation Foundation for Postgraduate.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

eEF2K, an atypical alpha-kinase, is responsible for regulating protein synthesis and energy homeostasis. Aberrant eEF2K function has been linked to various human cancers, including triple-negative breast cancer (TNBC). However, limited cellular activity of current eEF2K modulators impedes their clinical application. Based on the 2-phenyl-1,2,4-triazine-3,5(2H,4H)-dione scaffold of our hits I4 and C1, structure-activity relationship analysis led to the discovery of several more active derivatives (e.g., 19, 34, and 36) in inhibiting the viability of TNBC cell line MDA-MB-231. Moreover, the most potent compound 36 significantly suppresses the viability, proliferation, and migration of both MDA-MB-231 and HCC1806 cell lines. Mechanistically, compound 36 has a high binding affinity for the eEF2K protein and effectively induces its degradation. Additionally, 36 exerts a comparable tumor-suppressive effect to paclitaxel in an MDA-MB-231 cell xenograft mouse model with no obvious toxicity, demonstrating that compound 36 could be developed as a potential novel therapeutic for TNBC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsElongation Factor 2 KinaseTriazinesAntineoplastic AgentsCell ProliferationHumansStructure-Activity RelationshipAnimalsFemaleMiceCell Line, TumorMice, NudeXenograft Model Antitumor AssaysCell MovementDrug Screening Assays, AntitumorCell Survival

Substanzen

Elongation Factor 2 KinaseTriazinesAntineoplastic AgentsEEF2K protein, human

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
  • Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
  • Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha 410011, China.
  • Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China.
  • Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410011, China.
  • Key Laboratory of Diabetes Immunology, Central South University, Ministry of Education, Changsha 410011, China.

ORCID-Profile: Na Ye

Förderung

  • Fundamental Research Funds for Central Universities of the Central South University
  • Natural Science Foundation of Hunan Province
  • Hunan Provincial Innovation Foundation for Postgraduate
  • Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions
  • National Natural Science Foundation of China
  • Priority Academic Program Development of Jiangsu Higher Education Institutions

Zitieren

APA

Zhao, X., Zhong, C., Zhu, R., Gong, R., Liu, B., He, L., Tian, S., Jin, J., Jiang, T., Chen, J. L., Wan, X., Liu, W., Jiang, S., Deng, P., Cheng, Y., & Ye, N. (2024). Structure–Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2 H ,4 H )-dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01484

Vancouver

Zhao X, Zhong C, Zhu R, Gong R, Liu B, He L, et al. Structure–Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2 H ,4 H )-dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01484

BibTeX
@article{Zhao2024,
  author = {Zhao, Xiaobao and Zhong, Changxin and Zhu, Rongfeng and Gong, Rong and Liu, Bingyan and He, Linhao and Tian, Sheng and Jin, Jing and Jiang, Ting and Chen, Jing-Lei and Wan, Xiaoya and Liu, Wenjing and Jiang, Shilong and Deng, Pan and Cheng, Yan and Ye, Na},
  title = {Structure–Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2 H ,4 H )-dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01484}
}
Kostenlos starten →